NGM — NGM Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Brief: Ngm Bio Presents Updated Preliminary Findings For A Subgroup Of Patients With Advanced Prostate Cancer
Brief: NGM Bio Provides Business Highlights And Reports Q2 Financial Results
Brief: NGM Bio Appoints Siobhan Nolan Mangini To President, Chief Financial Officer
Brief: NGM Bio Announces Initiation Of Phase 1/1B Clinical Study Of NGM438 For Treatment Of Advanced Solid Tumors
NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: NGM Reports First Quarter 2022 Financial Results
NGM Biopharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: NGM Bio Announces Initiation Of Phase 1/1B Clinical Trial Of Ngm831 For The Treatment Of Patients With Advanced Solid Tumors
Brief: NGM Bio Announces Oral And Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio At Upcoming 2022 Aacr Annual Meeting
NGM Biopharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: NGM Bio Provides Business Highlights And Reports Fourth Quarter And Full Year 2021 Financial Results
NGM Biopharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Marathon Health Expands Board Of Directors
Brief: NGM Bio’S Ngm621 Receives Fast Track Designation From The FDA For The Treatment Of Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
Brief: NGM Bio Announces Clinical Trial Collaboration With Merck Related To Ongoing Phase 1/2 Trial Of NGM707 In Combination With Merck’s KEYTRUDA
Brief: NGM Bio Q3 Loss Per Share 37 CENTS
Brief: Ngm Bio Presents Early Findings From Ongoing Phase 1A/1B Study Of Ngm120 In Advanced Solid Tumors At ESMO 2021
Brief: NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, An ILT3 Antagonist Antibody
NGM Biopharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary